Everything below concerns REV-ERB agonist. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-04-16. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | SR9009; Stenabolic | Nickname is not a chemical name. |
| Typical analytical method | LC-MS/MS | Often with isotope-labeled internal standard. |
| Storage temperature | -20 °C | Desiccated and protected from light. |
| Solution stability | DMSO stock; avoid freeze-thaw | Store at -20 to -80 °C. |
| Regulatory status | Not approved; varies by country | May be restricted as research chemical. |
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
The first document, which was leaked at the end of January, was a "draft version of the Progressive Conservative government's upcoming health-care transformation legislation." CTV News said "local health integration networks, Cancer Care Ontario, eHealth Ontario, the Trillium Gift of Life Network and other government health agencies" would be "rolled into" the super agency. Minister Elliot said that the December 13 assistant deputy ministers workshop document, which made references to outsourcing laboratories, "inspections, licensing, devices" and Ornge, were options and that these services would not be privatized. The NDP said that the super agency was described in the leaked documents as having the "competency and capacity to effectively partner with public and private sector entities." The documents show that MyCare groups is being created as a "new model" of "integrated care delivery" with the goal of providing "patients with seamless, co-ordinated care and a single team of providers for all their care needs." Ontario Health Minister Christine Elliot tabled the controversial Bill 74: The People's Health Care Act. Its first reading was on February 26, 2019, and it received Royal Assent on April 18, 2019.
== Toxicity == Modern medicine finds that mercury is inherently toxic, and that its toxicity is not due to the presence of impurities. While mercury does have anti-microbial properties, and used to be widely used in Western medicine, its toxicity does not warrant the risk of using it as a health product in most circumstances. The Centers for Disease Control and Prevention have also reported a number of cases of lead poisoning associated with Ayurvedic medicine. Other incidents of heavy metal poisoning have been attributed to the use of rasashastra compounds in the United States, and arsenic has also been found in some of the preparations, which have been marketed in the United States under trade names such as "AyurRelief", "GlucoRite", "Acnenil", "Energize", "Cold Aid", and "Lean Plus". Ayurvedic practitioners claim that these reports of toxicity are due to failure to follow traditional practices in the mass production of these preparations for sale, however there is ample evidence of mercury and lead toxicity. The government of India has ordered that Ayurvedic products must specify their metallic content directly on the labels of the product; however, M. S. Valiathan noted that "the absence of post-market surveillance and the paucity of test laboratory facilities [in India] make the quality control of Ayurvedic medicines exceedingly difficult at this time."
== Ion source dependence == The ionization techniques available for MSI are suited to different applications. Some of the criteria for choosing the ionization method are the sample preparation requirement and the parameters of the measurement, as resolution, mass range and sensitivity. Based on that, the most common used ionization method are MALDI, SIMS AND DESI which are described below. Still, other minor techniques used are laser ablation electrospray ionization (LAESI), laser-ablation-inductively coupled plasma (LA-ICP) and nanospray desorption electrospray ionization (nano-DESI).
=== Physiologically based Pharmacokinetics === Physiologically-Based Pharmacokinetic models integrate physiological information to simulate drug behavior in various tissues and organs. These models consider organ-specific blood flow, tissue permeability, and drug properties, facilitating predictions of drug concentration at specific sites. PBPK models are instrumental in understanding complex drug behaviors.
Sources: en.wikipedia.org
== Nanomaterials in articles, patents, and products == The quantitative analysis of nanomaterials showed that nanoparticles, nanotubes, nanocrystalline materials, nanocomposites, and graphene have been mentioned in 400,000, 181,000, 144,000, 140,000, and 119,000 ISI-indexed articles, respectively, by September 2018. As far as patents are concerned, nanoparticles, nanotubes, nanocomposites, graphene, and nanowires have been played a role in 45,600, 32,100, 12,700, 12,500, and 11,800 patents, respectively. Monitoring approximately 7,000 commercial nano-based products available on global markets revealed that the properties of around 2,330 products have been enabled or enhanced aided by nanoparticles. Liposomes, nanofibers, nanocolloids, and aerogels were also of the most common nanomaterials in consumer products. The European Union Observatory for Nanomaterials (EUON) has produced a database (NanoData) that provides information on specific patents, products, and research publications on nanomaterials.
Norhydrocodone is the major metabolite of the opioid analgesic hydrocodone. It is formed from hydrocodone in the liver via N-demethylation predominantly by CYP3A4. Unlike hydromorphone, a minor metabolite of hydrocodone, norhydrocodone is described as inactive. However, norhydrocodone is actually an agonist of the μ-opioid receptor with similar potency to hydrocodone, but has been found to produce only minimal analgesia when administered peripherally to animals. This is likely due to poor blood-brain-barrier and thus central nervous system penetration.
For high-risk patients (white blood cell count >10,000/μL), treatment usually entails ATRA plus ATO along with the addition of chemotherapy (such as idarubicin) during induction to rapidly control leukocytosis and reduce early death and relapse risk. Effectiveness appears similar to Realgar/Indigo naturalis, which can be taken by mouth and is less expensive but is less available. It works by encouraging the proteosome breakdown of retinoic acid receptor alpha, by moving the protein on to the nuclear matrix and increasing ubiquitination. This use was approved for leukemia treatment in the United States in 2000. A liquid form of arsenic trioxide that can be given by mouth, (Oral-ATO; ARSENOL®) for the treatment of acute promyelocytic leukaemia.
Sources: en.wikipedia.org
=== 11 January === Russian Defence Minister Sergei Shoigu appointed Valery Gerasimov in place of Sergey Surovikin as overall commander of the war against Ukraine. Surovikin would serve as Gerasimov's deputy. The Wagner Group claimed around 500 Ukrainians were killed during the battle of Soledar.
=== Surgery === A minimally invasive surgical therapy called serial ultrasound-guided aspiration can be performed to treat breast mastitis in an outpatient setting, achieving a better cosmetic postoperative recovery. On the other side, nipple pain caused by tongue-tie can seek a surgical therapy called frenotomy on infants. In this surgery, the frenulum under the tongue will be clipped to improve latch and remove the restriction of tongue movement. Hence, breastfeeding efficiency can be improved. However, it may not instantly relieve nipple pain since infants probably have developed uncommon tongue movements.
The two substrates of this enzyme are (+)-neomenthol and oxidised nicotinamide adenine dinucleotide phosphate (NADP+). Its products are (−)-menthone, reduced NADPH, and a proton. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-OH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is (+)-neomenthol:NADP+ oxidoreductase. This enzyme is also called monoterpenoid dehydrogenase. This enzyme participates in monoterpenoid biosynthesis.
Sources: en.wikipedia.org
The most common approach is liquid chromatography-tandem mass spectrometry, often after extraction from blood, urine, or tissue. Ultraviolet detection and nuclear magnetic resonance spectroscopy are used mainly for reference material characterization. Isotope-labeled internal standards improve accuracy.
Solid material is usually kept at -20 °C, desiccated, and protected from light. Dimethyl sulfoxide stocks should be stored cold and subjected to minimal freeze-thaw cycles. Aqueous solutions are generally less stable and should be prepared fresh when possible.
Legality depends on the country and the intended use. It is not an approved medicine, and some places restrict or ban sales for human consumption. Buyers should verify local rules and product documentation before procurement.
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.